Market Challenges And Opportunities

Global Acute Ischemic Stroke (AIS) Market– Drivers

Increasing investment & funding scenario: Increasing investment & funding by key market players is expected to accelerate the market growth over the forecast period. For instance, in May 2022, the National Institute of Neurological Disorders and Stroke (NINDS), a part of the U.S. National Institutes of Health (NIH), awarded a US$ 4 Mn grant to the Keck School of Medicine to conduct a pivotal Phase 3 clinical trial of 3K3A-APC as a cerebroprotectant, a drug that hastens or augments recovery following tissue plasminogen activator (tPA) treatment for ischemic stroke.

Increasing research and development activities: Increasing research and development activities by key market players is expected to drive the market growth over the forecast period. For instance, In January 2023, Center Hospitalier Sud Francilien, a France-based hospital and medical company, compared early recanalization success rates in patients with acute distal vascular occlusion stroke and those treated with alteplase (ALT) to tenecteplase. (TNK), based on a retrospective analysis of magnetic resonance imaging (MRI) performed immediately after intravenous therapy (IVT). In the current study, researchers compared early sustained release rates in two lysis patients based on a retrospective review of magnetic resonance imaging (MRI) data obtained immediately after intravenous therapy (IVT).

Global Acute Ischemic Stroke (AIS) Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease spread to over 100 countries across the globe, and the World Health Organization (WHO), declared it a public health emergency on January 30, 2020.
COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others faced problems regarding transportation of things from one place to another.
However, the COVID-19 pandemic had positive impact on the global acute ischemic stroke (AIS) market, owing to increasing complication such as stroke caused by COVID-19. For instance, on September 06, 2022, according to the study published by Journal Brain, researchers reported that brain injury is common in the patients suffering from diseases like coronavirus disease 2019 (COVID-19) and influenza. COVID-19 is associated with neurologic complications such as stroke, autoimmune encephalitis, and Guillain-Barré syndrome. The physical brain injury were evident in COVID-19-related neurologic syndromes such as encephalitis and stroke. Various reports stated that COVID-19 is associated with brain injury that can occur even in the absence of a concomitant neurologic diagnosis.

Global Acute Ischemic Stroke (AIS) Market: Restraint

High cost of tissue plasminogen activator drugs: Factors such as high cost of tissue plasminogen activator drugs and termination of clinical trials are expected to hamper growth of the global acute ischemic stroke (AIS) market over the forecast period. For instance, in January 2021, according to an article published by Stroke & Vascular Neurology Journal, potential reasons for the low adherence rate of intravenous tissue plasminogen activator (IV-rt PA) in China was due to pre-hospital delay, lack of regional stroke care network, high cost of tPA, low insurance coverage, and concern about hemorrhagic risk. Also, according to the same source, hospitals achieving high adherence rate was seen in high-gross rating point (GRP) per capita areas.
Counterbalance: Key players are focusing on reducing drug cost